Pneumococcal pneumonia in adults – Re-emergence of vaccine serotypes: a prospective multicentre cohort study in Germany, 2020-2023
Authored by Christina Bahrs, Norman Rose, Grit Barten-Neiner, Carolin Fleischmann-Struzek, Mark P. G. van der Linden, Gernot Rohde, Jan Rupp, Martin Witzenrath, Jessica Rademacher, and Mathias W. Pletz
Posted
Server
medRxiv
DOI
10.1101/2025.10.24.25338303
This prospective multicentre study investigated pneumococcal serotype distribution and vaccine coverage of the 13- and 20-valent conjugate vaccines, and the 23-valent polysaccharide vaccine among adults with community-acquired pneumonia in Germany, from 2020 to 2023, using serotype-specific urine antigen detection testing. The findings show that
Streptococcus pneumoniae
has reemerged as causative pathogen of pneumonia, particularly in adults aged ≥60 years. This resurgence, observed during the ongoing SARS-CoV-2 pandemic, has been primarily driven by an increase in cases due to serotype 3.
You can write a PREreview of Pneumococcal pneumonia in adults – Re-emergence of vaccine serotypes: a prospective multicentre cohort study in Germany, 2020-2023. A PREreview is a review of a preprint and can vary from a few sentences to a lengthy report, similar to a journal-organized peer-review report.
Before you start
We will ask you to log in with your ORCID iD. If you don’t have an iD, you can create one.
What is an ORCID iD?
An ORCID iD is a unique identifier that distinguishes you from everyone with the same or similar name.